One To Watch

Sanofi

A French multinational pharmaceutical company and the world's largest vaccine producer, pursuing a focused strategy in immunology, rare diseases, and oncology with a clinical pipeline of 80 programmes and up to 19 new medicines targeted for launch by 2030.

Company Overview

Sanofi is a global biopharmaceutical company headquartered in Paris, France, and one of the world's leading pharmaceutical enterprises by revenue. The company discovers, develops, manufactures, and markets medicines and vaccines across immunology, rare diseases, oncology, neurology, cardiovascular disease, and infectious diseases. Through its subsidiary Sanofi Pasteur, Sanofi is the world's largest producer of vaccines. The company has approximately 100,000 employees worldwide and generated revenues in excess of €43 billion. Sanofi's R&D pipeline encompasses 80 clinical-stage projects, with 34 in Phase 3 or under regulatory review. Up to 19 new medicines are targeted for launch by the end of the decade, anchored by a highly innovative immunology portfolio.

Headquarters and Global Presence

Sanofi is headquartered in Paris, Île-de-France, France. The company has significant R&D operations in Cambridge, Massachusetts, Frankfurt, Germany, and Lyon, France, as well as manufacturing and commercial operations spanning more than 60 countries. Its global manufacturing network produces both pharmaceutical products and vaccines, with Sanofi Pasteur operating dedicated vaccine production facilities across multiple continents. Sanofi markets its products globally, with particular commercial strength in Europe, North America, and emerging markets. The company has established strategic collaboration networks in Asia, including partnerships with South Korea's SK bioscience in vaccines.

Founding and History

Sanofi was founded on 15 February 1973 as a subsidiary of Elf Aquitaine, a French state-owned oil company seeking to diversify its portfolio through pharmaceutical investment. The company initially absorbed several smaller firms, and by 1979 had consolidated all pharmaceutical activities under a single organisation. Sanofi went public on the Paris stock exchange in 1979. In 1999, Sanofi merged with Synthélabo to form Sanofi-Synthélabo. A transformative merger with Aventis in 2004 created Sanofi-Aventis, one of the largest pharmaceutical companies in the world. The company reverted to the name Sanofi in May 2011, reflecting a strategic refocusing. Subsequent years saw the acquisition of Genzyme for $20 billion, establishing Sanofi as a leader in rare diseases, and the approval of Dupixent (dupilumab) as one of the most commercially successful immunology medicines ever developed.

Therapy Areas and Focus

Sanofi's strategy is anchored in immunology, rare diseases, and oncology. In immunology, the company has achieved extraordinary commercial success with Dupixent (dupilumab), approved across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, and prurigo nodularis, and is pursuing next-generation agents including amlitelimab (anti-OX40L) and frexalimab (anti-CD40L). In rare diseases, Sanofi's Genzyme heritage underpins treatments for lysosomal storage diseases and haematology. In oncology, the acquisition of Blueprint Medicines adds targeted therapies including Ayvakit for systemic mastocytosis. The company has divested its consumer healthcare business (Opella) to focus exclusively on prescription medicines.

Technology Platforms and Modalities

Sanofi's scientific platform spans monoclonal antibodies, bispecific antibodies, enzyme replacement therapies, and RNA-based approaches. Dupixent exemplifies the company's leadership in cytokine-blocking immunology, inhibiting the shared IL-4/IL-13 receptor. Amlitelimab targets OX40-ligand to suppress T helper cell differentiation upstream of cytokines, representing a novel mechanism in type 2 inflammation. Frexalimab is an anti-CD40L antibody being studied in multiple sclerosis and other immune diseases. The collaboration with Earendil Labs introduces AI-driven bispecific antibody discovery. Sanofi's acquisition of Dynavax in December 2025 added differentiated adjuvant technology and vaccine assets. The company is actively embedding AI across its R&D processes as part of its digital transformation strategy.

Key Pipeline and Programs

Amlitelimab, Sanofi's anti-OX40L antibody, has demonstrated robust Phase 3 efficacy in moderate-to-severe atopic dermatitis, with two additional studies (AQUA and ESTUARY) expected to report in H2 2026; it is projected among drugs with potential peak sales exceeding €5 billion. Frexalimab, in Phase 2 for multiple sclerosis and other autoimmune conditions, showed promising early results. Duvakitug and lunsekimig are further immunology assets in Phase 3. SAR441566 is an oral TNF blocker also in late-stage development. The AIRCULES Phase 2 study in moderate-to-severe asthma and an itepekimab study in bronchiectasis are expected to read out in 2026. Ayvakit/Ayvakyt (Blueprint Medicines acquisition) is approved for systemic mastocytosis. The pipeline includes 34 Phase 3 or regulatory submission programmes across all areas.

Key Personnel

Belén Garijo took over as Chief Executive Officer of Sanofi on 29 April 2026, becoming the first woman to lead the company. She previously served as CEO of Merck KGaA from 2021 and has 15 years of prior experience at Sanofi. Board member Olivier Charmeil served as acting CEO during the transition following the departure of Paul Hudson in February 2026. Dietmar Berger serves as Global Head of Development and Chief Medical Officer, overseeing the clinical pipeline. Houman Ashrafian serves as Chief Scientific Officer, leading scientific strategy. Peter Guenter leads the commercial business as Chief Commercial Officer.

Strategic Partnerships

Sanofi's most commercially important partnership is with Regeneron Pharmaceuticals, with whom it co-developed and co-commercialises Dupixent and Kevzara. This alliance has generated tens of billions of dollars in combined revenues. The acquisition of Blueprint Medicines for approximately $9.1 billion (with up to $6 per share in contingent payments) brings Ayvakit/Ayvakyt for systemic mastocytosis. The December 2025 acquisition of Dynavax adds adjuvant technology and vaccine capabilities. A $2.5 billion collaboration with Earendil Labs targets AI-driven bispecific antibody discovery for autoimmune diseases, building on a prior $1.7 billion agreement. Sanofi has also partnered with ABL Bio for the blood-brain barrier bispecific antibody ABL301 in CNS disease. In vaccines, SK bioscience is a central global collaboration partner.

FAQ Section

Sanofi's central strategic issue is sustaining momentum and commercial execution under new CEO Belén Garijo following the abrupt leadership transition in early 2026, while successfully launching amlitelimab and other next-generation immunology assets to extend its blockbuster franchise beyond Dupixent as it faces eventual patent lifecycle pressures.

OX40-ligand drives the differentiation and survival of T helper cells upstream of multiple inflammatory cytokines, making anti-OX40L therapy with amlitelimab a potentially broader mechanism for controlling type 2 inflammation in atopic dermatitis and other allergic conditions than existing cytokine-directed antibodies like dupilumab.

Sanofi differentiates itself through its 'pipeline-in-a-product' immunology strategy, where amlitelimab, frexalimab, and SAR441566 are each individually projected to exceed €5 billion in peak sales, combined with its unrivalled global vaccine manufacturing through Sanofi Pasteur and its orphan disease heritage through the Genzyme franchise.

Amlitelimab represents the most advanced anti-OX40L therapy in clinical development, with Phase 3 data in atopic dermatitis demonstrating durable disease control through a mechanism upstream of IL-4, IL-13, and other key cytokines, potentially enabling treatment of patients who do not adequately respond to existing biologic therapies.

Sanofi's pipeline of 80 clinical-stage programmes is defined by immunology and inflammation—including atopic dermatitis, asthma, multiple sclerosis, and IBD—rare diseases through the Genzyme heritage, oncology expanding through Blueprint Medicines, and vaccines through Sanofi Pasteur and the Dynavax adjuvant platform.

Sanofi is a mature commercial pharmaceutical company generating revenues in excess of €43 billion, undergoing a strategic transformation under new leadership, with its existing Dupixent franchise driving current growth while a deep immunology pipeline is expected to underpin the next generation of commercial success through the end of the decade.

Key watchpoints include Phase 3 results from AQUA and ESTUARY studies for amlitelimab in H2 2026, the early strategic priorities of incoming CEO Belén Garijo, integration of the Blueprint Medicines acquisition and Ayvakit commercial ramp, Phase 2 data for frexalimab in multiple sclerosis, and the continued commercial trajectory of Dupixent across its growing list of approved indications.

Want to Update your Company's Profile?